Core Insights - Chuangxin International has completed nearly 100 million RMB in Series B financing, led by Yueke Fund and Zhongshan Haochuang Fund, to accelerate the development and global commercialization of organoid technology [2] - The company focuses on precision medicine, new drug development, and intelligent manufacturing, aiming to overcome key industry bottlenecks and promote the intelligent, standardized, and industrialized development of the organoid industry [2][3] - The FDA's new regulation set to be released in April 2025 will phase out animal testing models, recommending human cell models, including organoids, marking a shift towards more realistic human models in life sciences research [2] Company Overview - Chuangxin International Biotech (Guangzhou) Co., Ltd. was established in March 2018 and has built a comprehensive ecosystem covering the entire lifecycle of organoid technology [2] - The company is positioned as a global leader in organoid technology, redefining core pathways in life sciences research through technological innovation and ecosystem reconstruction [3] - The CEO, Dr. Huang Min, stated that the company will leverage this financing round to enhance its technology platform, data intelligence, and industrial applications, aiming to create a product matrix in key areas such as organoid intelligent devices and data systems [3]

创芯国际董事长兼CEO黄敏表示，感谢粤科基金、投控东海及各投资方的高度认可和战略支持。创芯国 际将以此轮融资为契机，以'技术平台+数据智能+产业应用'三维驱动，构建覆盖类器官全生命周期的技 术生态体系，继续加大核心技术研发、产品创新，在类器官智能设备与芯片、数据智能系统等关键赛道 形成产品矩阵，推动技术突破与产业化升级，致力于成为类器官产业全球领航者。 采写：南都·湾财社记者 徐劲聪 据悉，创芯国际是一家类器官领域全产业链创新企业，依托自主创新的核心技术体系，率先构建了覆盖 类器官全生命周期技术一体化生态平台。公司聚焦精准医疗、新药研发与智能智造三大战略方向，围绕 类器官肿瘤治疗、再生医学、合成生物学三大领域的规模化应用，推动类器官行业向智能化、标准化、 产业化方向发展。 作为联合领投方，广东国资投资机构粤科基金方面表示，创芯国际拥有领先的类器官技术和产业化平 台，其技术成果在精准医疗、新药研发等前沿领域应用价值巨大，符合粤科基金聚焦科技核心赛道的投 资理念，相信创芯国际将在行业变革中占据关键位置。 深投控旗下专注早中期科创企业投资的投控东海表示，认可创芯国际的技术深度与成长潜力。本次投资 不仅是投控东海在生 ...